Author’s response to reviews

Title: Switching from glargine+insulin aspart to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control - A prospective cohort study

Authors:
Jing Li (627168316@qq.com)
Liming Wang (wlmyjjw@163.com)
Fen Chen (chenfen-03@163.com)
Dongxia Xia (xia-1216@163.com)
Lingling Miao (27790351@QQ.COM)

Version: 3 Date: 20 Sep 2018

Author’s response to reviews:

Editor Comments:

1. In your “ethical approval and consent to participate” section, please confirm whether informed consent, written or verbal, was obtained from all participants and clearly state this in your manuscript. If verbal, please state the reason and whether the ethics committee approved this procedure. If the need for consent was waived by an IRB or is deemed unnecessary according to national regulations, please clearly state this, including the name of the IRB or a reference to the relevant legislation.

Response: Written informed consent was obtained from all patients.

2. We strongly encourage all authors to share their raw data, either by providing it in a supplementary file or depositing it in a public repository and providing the details on how to access it in this section. If you do not wish to share your data, please clearly state this in this
section along with a justification. Data availability statements can take one of the following forms (or a combination of more than one if required for multiple datasets):

Response: The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

3. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Response: Done.